Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Bewertung der Therapietreue bei Apalutamid bei Teilnehmern mit metastasierendem hormonsensiblem Prostatakrebs in Frankreich (OBSAPA)

2. November 2026 aktualisiert von: Janssen Cilag S.A.S.

Eine OBServationale prospektive Studie in Frankreich: Adhärenz zu APAlutamid bei Patienten mit metastasiertem hormonsensiblem Prostatakrebs (mHSPC) in Frankreich

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

Studienübersicht

Status

Rekrutierung

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

540

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Caen, Frankreich, 14076
        • Rekrutierung
        • Centre Francois Baclesse

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adult male (according to their chromosomal composition at birth) participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide.

Beschreibung

Inclusion criteria:

  • Male (based on chromosomal composition at birth) and aged greater than or equal to (>=) 18 years.
  • Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
  • Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy [ADT]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
  • Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
  • Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
  • Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide

Exclusion criteria:

  • Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
  • Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
  • Is currently receiving active treatment for prostate cancer as part of an interventional study
  • Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
  • Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
  • Beneficiary of State Medical Aid [AME]
  • Does not speak/read French
  • Under guardianship or curatorship
  • Under judicial protection

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Metastatic hormone-sensitive prostate cancer (mHSPC): Routine Clinical Practice Setting

Participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide (Month 0) in routine clinical practice and will be followed up until 12 months after end of study visit (Month 12). No intervention will be administered as a part of this study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With Adherence to Apalutamide at 12 Months
Zeitfenster: At 12 months

Adherent participants are defined as participants adherent to apalutamide at every visit until 12 months according to the Medication Adherence Report Scale (MARS-5). MARS-5 is a well-known participant-reported adherence measure (PRAM) consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation
Zeitfenster: At 12 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical Risk Factor Among Adherent and Non-adherent Participants: ECOG Status
Zeitfenster: Up to 12 months

Clinical risk factors for treatment the Eastern Cooperative Oncology Group (ECOG) will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Comorbidities
Zeitfenster: Up to 12 months

Clinical risk factors for treatment prostate comorbidities will be reported.

Up to 12 months
Clinical Factors of Adherence at 12 Months: Disease Volume
Zeitfenster: At 12 months

Predictive clinical factors of adherence that is disease volume at 12 months will be reported.

At 12 months
Percentage of Adherent Participants at 3, 6, and 9 Months
Zeitfenster: At 3,6,9 months

Percentage of adherent participants at 3 months, 6 months and 9 months according to the MARS-5 will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication. Participants are asked to evaluate how often they adopt each behavior with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3,6,9 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation at 3, 6 and 9 Months
Zeitfenster: At 3, 6 and 9 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3, 6 and 9 months
Number of Participants with Risk of Non-Adherence as per Social, Psychological, Usage and Rational (SPUR) Factors as per SPUR Adherence Tool
Zeitfenster: Baseline, Months 3, 6, 9 and 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

Baseline, Months 3, 6, 9 and 12
Spearman Correlation Coefficients at Baseline and Month 12
Zeitfenster: At Baseline and Month 12

Spearman correlation coefficients between each of the 13 behavioral drivers will be reported.

At Baseline and Month 12
SPUR Global Risk Score at Baseline and Month 12
Zeitfenster: At Baseline and Month 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

At Baseline and Month 12
Functional Assessment of Cancer Therapy- Prostate (FACT-P) Score
Zeitfenster: At Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life (QoL) in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4, and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

At Baseline, Months 3, 6, 9, 12
Change from Baseline in FACT-P Score at 3, 6 and 9 Months
Zeitfenster: Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4 , and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

Baseline, Months 3, 6, 9, 12
Demographics Characteristics of Participants: Age
Zeitfenster: Baseline

The demographic characteristics of participants that is, age will be reported.

Baseline
Demographics Characteristics of Participants: Socio-Professional Category
Zeitfenster: Baseline

The demographic characteristics of participants that is, socio-professional category (the participant's last occupation held prior to retirement: Managerial [higher managerial or lower managerial], Non-managerial [intermediate or small employers or lower supervisory or semi-routine or routine], Never worked or long-term unemployed will be reported.

Baseline
Demographics Characteristics of Participants: G8 Geriatric Screening Score
Zeitfenster: Baseline

The demographic characteristics of participants that is, G8 geriatric screening score will be reported. The G8 consists of eight items: participant age (greater than [>]85, 80-85, less than [<]80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with higher scores indicating a lower risk of impairments.

Baseline
Prostate-Specific Antigen (PSA) Level at Androgen-Deprivation Therapy (ADT) Initiation
Zeitfenster: Up to 12 months

PSA levels at ADT initiation will be reported.

Up to 12 months
PSA Level at Baseline
Zeitfenster: At Baseline

PSA levels at baseline will be reported.

At Baseline
Change from Baseline in PSA Levels
Zeitfenster: Baseline up to 12 months

Change from baseline in PSA levels will be reported.

Baseline up to 12 months
Serum Testosterone at Baseline
Zeitfenster: At baseline

Serum testosterone levels will be reported.

At baseline
Time from Initial Diagnosis of Prostate Cancer to Metastatic Stage
Zeitfenster: Baseline up to 12 months

Time from initial diagnosis of prostate cancer to metastatic stage for metachronous participants will be reported.

Baseline up to 12 months
Type of Imaging Methods Used for Cancer Diagnostics
Zeitfenster: Baseline

Number of participants with different type of imaging methods used for cancer diagnostic (for example, magnetic resonance imaging [MRI], Prostate Specific Membrane Antigen Positron Emission Tomography [PSMA-PET], Positron emission tomography [PET] choline, Computed Tomography scan [CT scan], bone scan) will be reported.

Baseline
Osteodensitometry Score
Zeitfenster: Baseline

Osteodensitometry score, a type of imaging method used for cancer diagnostic will be reported.

Baseline
Tumor assessment: Location of Metastases
Zeitfenster: Baseline

Location of metastases as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
Tumor assessment: Number of Lesions
Zeitfenster: Baseline

Number of lesions as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
ECOG Performance Status
Zeitfenster: At Baseline

ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.

At Baseline
Number of Participants with History of Treatment for Prostate Cancer
Zeitfenster: Baseline

Participants with history of treatment for prostate cancer will be reported.

Baseline
Number of Participants Reporting Concomitant Diseases
Zeitfenster: Baseline

Participants with Current concomitant diseases (co-morbidities) will be reported.

Baseline
Number of Participants With Vital Sign Assessments
Zeitfenster: Baseline

Participants with relevant vital sign assessment (blood pressure and pulse) will be reported.

Baseline
Time from Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Diagnosis to Treatment Initiation
Zeitfenster: Baseline up to 12 months

Time from mHSPC diagnosis to treatment initiation is defined as the time between date of mHSPC diagnosis and first administration of apalutamide.

Baseline up to 12 months
Percentage of Participants Reaching Undetectable PSA
Zeitfenster: At Months 3,6,9,12

Percentage of participants with undetectable PSA levels that is PSA level less than or equal to (<=) 0.2 nanogram per milliliter (ng/mL) will be reported.

At Months 3,6,9,12
Percentage of Participants Reaching Ultralow (UL) PSA
Zeitfenster: At Months 3,6,9,12

Percentage of participants with ultralow PSA levels that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Time to Undetectable PSA
Zeitfenster: Up to 12 months

Time to undetectable PSA is defined as the time between first administration of apalutamide and date of undetectable PSA.

Up to 12 months
Time to UL PSA
Zeitfenster: Up to 12 months

Time to UL PSA is defined as the time between first administration of apalutamide and date of UL PSA.

Up to 12 months
Number of Participants with Greater Than or Equal to (>=) 50% Decline in PSA Values (PSA 50) from Baseline
Zeitfenster: Baseline up to 12 months

Participants with >=50% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with >= 90% Decline in PSA Values (PSA 90) from Baseline
Zeitfenster: Baseline up to 12 months

Participants with >=90% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with Decrease in PSA Levels (PSA Halving-time)
Zeitfenster: Up to 12 months

Participants with decrease in PSA levels (PSA halving-time) over time will be reported.

Up to 12 months
Progression-Free Survival (PFS)
Zeitfenster: At Months 3,6,9,12

PFS is defined as the time from initiation of apalutamide until earliest record of disease progression determined by physician's assessment, or death.

At Months 3,6,9,12
Number of Deaths
Zeitfenster: At Months 3,6,9,12

The number of deaths at months 3,6,9 and 12 will be reported.

At Months 3,6,9,12
Number of Participants Reporting Change Since Baseline in Apalutamide and ADT Modalities
Zeitfenster: At Baseline, Months 3,6,9,12

Participants reporting changes since baseline in Apalutamide and ADT Modalities (that is, dose, route of administration, number of tablets, time of intake) will be reported.

At Baseline, Months 3,6,9,12
Time from mHSPC Diagnosis to ADT Treatment Initiation
Zeitfenster: Baseline up to Month 12

Time from mHSPC diagnosis to ADT treatment initiation will be reported.

Baseline up to Month 12
Time Between ADT and Apalutamide Treatment Initiation
Zeitfenster: Baseline up to Month 12

Time between ADT and apalutamide initiation will be reported.

Baseline up to Month 12
Number of Participants with Apalutamide Treatment Discontinuation
Zeitfenster: At Months 3,6,9,12

Participants who have discontinued apalutamide treatment will be reported.

At Months 3,6,9,12
Reasons for Discontinuation of Apalutamide Treatment
Zeitfenster: At Months 3,6,9,12

Participants who have discontinued apalutamide treatment and the reasons for discontinuation will be reported.

At Months 3,6,9,12
Time to Discontinuation of Apalutamide Treatment
Zeitfenster: At Months 3,6,9,12

Time to discontinuation of apalutamide treatment will be reported.

At Months 3,6,9,12
Number of Participants Receiving Planned Subsequent Treatment for Prostate Cancer
Zeitfenster: At Months 3,6,9,12

Participants receiving planned subsequent treatment for prostate cancer will be reported.

At Months 3,6,9,12
Percentage of Participants who Consulted for Treatment
Zeitfenster: At Months 3,6,9,12

The percentage of participants who consulted for treatment will be reported.

At Months 3,6,9,12
Percentage of Participants who Used Caregiver Support
Zeitfenster: At Months 3,6,9,12

Percentage of participants who use caregiver support will be reported.

At Months 3,6,9,12
Number of Participants Receiving Concomitant Treatments
Zeitfenster: At Baseline, Months 3,6,9,12

Participants receiving concomitant treatments will be reported.

At Baseline, Months 3,6,9,12
Number of Participants with a Change in Concomitant Treatments
Zeitfenster: At Months 3,6,9,12

Participants with a change in concomitant treatments will be reported.

At Months 3,6,9,12
Number of Participants Experiencing At Least One Adverse Event (AE)
Zeitfenster: At Months 3,6,9,12

An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An adverse event does not necessarily have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product or is medically important. Severity of AEs will be graded as follows: Mild (Easily tolerated symptoms), Moderate (Sufficient discomfort, causes interference with normal activity) and Severe (Extreme distress).

At Months 3,6,9,12
Percentage of Undetectable PSA According to Adherence Levels
Zeitfenster: At Months 3,6,9,12

Percentage of undetectable PSA according to adherence levels, that is PSA level <= 0.2 ng/mL will be reported.

At Months 3,6,9,12
Percentage of UL PSA According to Adherence Levels
Zeitfenster: At Months 3,6,9,12

Percentage of UL PSA according to adherence levels, that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Number of Participants with PSA 50 Response According to Adherence Levels
Zeitfenster: At Months 3,6,9, and 12

Participants with >=50% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Number of Participants with PSA 90 Response According to Adherence Levels
Zeitfenster: At Months 3,6,9, and 12

Participants with >=90% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Concomitant Treatments
Zeitfenster: Up to 12 months

Participants using the concomitant treatments will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Prostate Specific Antigen (PSA) Rate
Zeitfenster: Up to 12 months

Clinical risk factors for prostate specific antigen (PSA) rate will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Socio-professional Category
Zeitfenster: Up to 12 months

Participants with socio-professional category will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Disease Specialized Consultations
Zeitfenster: Up to 12 months

Participants reporting the use of disease specialized consultations will be reported.

Up to 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Janssen-Cilag France Clinical Trial, Janssen-Cilag France

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. Dezember 2025

Primärer Abschluss (Geschätzt)

3. Januar 2028

Studienabschluss (Geschätzt)

18. September 2028

Studienanmeldedaten

Zuerst eingereicht

26. Januar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. März 2026

Zuerst gepostet (Tatsächlich)

5. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • 56021927MPC4009

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .